Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 619-290-0 | CAS number: 97780-06-8
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Basic toxicokinetics
Administrative data
- Endpoint:
- basic toxicokinetics in vivo
- Type of information:
- experimental study
- Adequacy of study:
- supporting study
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- test procedure in accordance with national standard methods
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 987
- Report date:
- 1987
Materials and methods
- Objective of study:
- distribution
- excretion
Test guideline
- Qualifier:
- no guideline followed
- Principles of method if other than guideline:
- This study was designed to follow the elimination and distribution of the 14C-labeled test substance after oral administration in male and female rats.
- GLP compliance:
- yes
Test material
- Reference substance name:
- Reference substance 002
- Cas Number:
- 97780-06-8
- Test material form:
- solid
- Details on test material:
- Purity: Not reported
Constituent 1
- Radiolabelling:
- yes
- Remarks:
- Labeled on both the phenyl and trizaine groups of the molecule
Test animals
- Species:
- rat
- Strain:
- other: Crl:CD(SD)
- Sex:
- male/female
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- other: acetone:corn oil (3/7,v/v) mixture
- Duration and frequency of treatment / exposure:
- Animals will be maintained in individual metabolism cages for 7 days after the radioactive dose is administered or until 90+ percent of the administered dose is excreted (whichever occurs first), at which time the animals should be sacrificed.
Doses / concentrationsopen allclose all
- Dose / conc.:
- 10 mg/kg bw (total dose)
- Remarks:
- No preconditioning; Each animal will receive, by gavage, one low-dose dose (10 mg) of the test substance. This dose will consist of 0.5 mg of the 14C-triazine labeled moiety and an appropriate amount of the unlabeled test substance (Group A)
- Dose / conc.:
- 10 mg/kg bw (total dose)
- Remarks:
- Each animal will receive, by gavage, a daily dose of 10 mg/kg of the non-radioactive test substance for 14 consecutive days followed 24 hours later by a single 10 mg/kg gavage dose of the test substance containing 0.5 mg of the 14C-triazine labeled moiety and an appropriate amount of the unlabeled test substance (Group B)
- Dose / conc.:
- 1 000 mg/kg bw (total dose)
- Remarks:
- No preconditioning; Each animal will receive, by gavage, a single high-dose (1000 mg/kg) of the test substance. This dose will consist of 0.5 mg of the 14C-triazine labeled moiety and an appropriate amount of the unlabeled test substance (Group C)
- Dose / conc.:
- 1 000 mg/kg bw (total dose)
- Remarks:
- No preconditioning; Each animal will receive by gavage, one high-dose (1000 mg/kg) of the test substance. This dose will consist of 0.5 mg of the 14C-phenyl labeled moiety and an appropriate amount of the unlabeled test substance.
- No. of animals per sex per dose / concentration:
- Preliminary study: One male and one female rat in each group (A, B, C, and D)
Main study: Four male and four female rats in each group (A, B, C, and D) - Control animals:
- no
- Positive control reference chemical:
- No
- Details on dosing and sampling:
- TOXICOKINETIC / PHARMACOKINETIC STUDY (Absorption, distribution, excretion)
- Tissues and body fluids sampled: urine, faeces, expired air, blood, carcass, GI tract, whole organs, skin, muscle, fat, bone (femurs), cage washes, and residual feed
- Time and frequency of sampling: Urine, feces, and expired air at 12 and 24 hours post-dosing and at each succedlng 24-houri Interval until sacrlfice. Blood and other tissues following sacrfice of the animals
METABOLITE CHARACTERISATION STUDIES
- Tissues and body fluids sampled: urine and faeces
- From how many animals: 8 (samples pooled or not): Yes
- Method type(s) for identification: liquid scintillation counting (LSC) - Statistics:
- The means have been compared using student's t test. Only significant differences with a "P" value less than 0.01 have been recorded.
Results and discussion
- Preliminary studies:
- Only very low levels of radioactivity < 0.01% were detected in the organic trapping agent (Carbosorb) surrounded by ice. Radioactivity could only be detected after 96 hours in the pre-conditioned group (Group B). Immediately after administration of the high dose (Groups C and D), the rats (male and female) appeared to breathe with difficulty and were sleepy. After about one hour female rats CF1 and DF1 were in a lethargic state, with breathing difficulties and were non responsive to external stimuli. After about three hours, the condition was about the same but female DF1 exhibited strong eye irritation with tear production. At twelve hours after administration, the condition had not changed much but, after 24 hours, all rats appeared to be normal.
Main ADME results
- Type:
- excretion
- Results:
- Groups A-C excreted > 90% of the administered radioactivity after two days. Group D excreted > 80% of the administered radioactivity after two days.
Toxicokinetic / pharmacokinetic studies
- Details on excretion:
- Group A (10 mg/kg of the triazine-labeled moiety): All animals excreted> 90% of the administered radioactivity after two days. The mean total recovery from males was 100.0 ± 4.7% (urine 59.3 ± 4.1%, feces 40.3 ± 5.8%) with a mean residual level of radioactivity in the body of 0.08 ± 0.04%. The corresponding recovery in females was 97.5 ± 5.3% (urine 57.3 ± 1.2%, feces 39.9 ± 5.9%) with 0.08 ± 0.03% remaining in the body. The concentration of radioactivity in all organs and tissues was below 0.1 ppm.
Group B: (Preconditioned: 10 mg/kg of the triazine-labeled moiety): All animals excreted> 90% of the administered radioactivity after two days. The mean total recovery from males was 105.9 ± 3.1% (urine 44.5 ± 3.2%, feces 61.1 ± 5.6%) with a mean residual level of radioactivity in the body of 0.05 ± 0.01%. The corresponding recovery in females was 104.0 ± 1.7% (urine 50.5 ± 2.7%, feces 53.1 ± 1.5%) with 0.07 ± 0.01% remaining in the body. The concentration of radioactivity in all organs and tissues was below 0.1 ppm.
Group C (1000 mg/kg of the triazine labeled moiety): All males excreted > 90% of the administered radioactivity after three days. All surviving female rats excreted > 80% of the administered radioactivity after three days. The mean total recovery from males was 98.8 ± 5.7% (urine 49.3 ± 5.5%, feces 48.9 ± 4.5%) with a mean total of 0.12 ± 0.07% remaining in the body. The corresponding recovery in females was 95.5 ± 2.2% (urine 52.5 ± 5.0%, feces 42.3 ± 7.1%) with 0.12 ± 0.01% remaining in the body. The concentration of radioactivity in the organs and tissues ranged from "not detectable" to about 8.8 ppm in the kidneys.
Group D (1000 mg/kg of the phenyl-labeled moiety): All male rats excreted > 90% of the administered radioactivity after three days. All surviving female rats excreted > 80% of the administered radioactivity after three days. The mean total recovery from males was 101.0 ± 4.3% (urine 51.3 ± 9.2%, feces 48.9 ± 6.7%) with a mean total of 0.04 ± 0.02% remaining in the body. The corresponding recovery in females was 93.8 ± 8.6% (urine 39.6 ± 16.3%, feces 53.5 ± 7.8%) with 0.13 ± 0.13% remaining in the body. The concentration of radioactivity in the organs and tissues ranged from "not detectable" to about 11 ppm in the fat.
Metabolite characterisation studies
- Metabolites identified:
- yes
- Details on metabolites:
- The test substance is moderately metabolized (~ 50%) when administered orally to rats at a low- dose level (10 mg/kg), both with and without preconditioning, and at a high-dose level (1000 mg/kg). An overall similarity of male and female metabolism of the test substance was demonstrated. Two major metabolites were identified by LC/MS as the N-Demethyl and the O-Deethyl metabolite. A minor metabolite, which was found consistently in all samples analyzed, was identified as the Free Acid. A dose-dependent metabolism was observed. At the low-dose level, the N-Demethyl metabolite was the major metabolite in urine; whereas at the high-dose level, the O-Deethyl metabolite was the predominant metabolite in the urine.
Applicant's summary and conclusion
- Conclusions:
- Four groups of male and female rats were administered single oral gavage doses of the test substance (Group A was administered 10 mg/kg of the 14C-triazine labeled moiety without preconditioning), Group B was administered 10 mg/kg of the 14C-triazine labeled moiety with preconditioning, Group C was administered 1000 mg/kg of the 14C-triazine labeled moiety without preconditioning, and Group D was administered 1000 mg/kg of the 14C-phenyl labeled moiety without preconditioning.
The test substance is moderately metabolized (~ 50%) when administered orally to rats at a low- dose level (10 mg/kg), both with and without preconditioning, and at a high-dose level (1000 mg/kg). An overall similarity of male and female metabolism of the test substance was demonstrated. Two major metabolites were identified by LC/MS as the N-Demethyl and the O-Deethyl metabolite. A minor metabolite, which was found consistently in all samples analyzed, was identified as the Free Acid. A dose-dependent metabolism was observed. At the low-dose level, the N-Demethyl metabolite was the major metabolite in urine; whereas at the high-dose level, the O-Deethyl metabolite was the predominant metabolite in the urine.
For the low-dose groups (Groups A and B), greater than 90% of the dose was excreted within 2 days. For Group A without preconditiong, 57-59% was excreted in the urine with about 40% in the feces. The concentration of radioactivity in all organs and tissues was below 0.1 ppm. For the high-dose groups (Groups C and D), greater than 80-90% of the dose was excreted within 3 days. Males administered either the triazine or phenyl-labeled moieties, excreted similar amounts in the urine and feces while in the females administered the 14C-triazine labeled moiety, 52% of the radioactivity was found in the urine and 42% in the feces and for the females administered the phenyl-labeled moiety, 40% of the radioactivity was found in the urine and 50% in the feces. The concentration of radioactivity in the organs and tissues in Group C ranged from "not detectable" to about 8.8 ppm in the kidneys and in Group D, the concentration of radioactivity in the organs and tissues ranged from "not detectable" to about 11 ppm in the fat. - Executive summary:
Four groups of male and female rats were administered single oral gavage doses of the test substance (Group A was administered 10 mg/kg of the 14C-triazine labeled moiety without preconditioning), Group B was administered 10 mg/kg of the 14C-triazine labeled moiety with preconditioning, Group C was administered 1000 mg/kg of the 14C-triazine labeled moiety without preconditioning, and Group D was administered 1000 mg/kg of the 14C-phenyl labeled moiety without preconditioning.
All Group A animals excreted > 90% of the administered radioactivity after two days. The mean total recovery from males was 100.0 ± 4.7% (urine 59.3 ± 4.1%, feces 40.3 ± 5.8%) with a mean residual level of radioactivity in the body of 0.08 ± 0.04%. The corresponding recovery in females was 97.5 ± 5.3% (urine 57.3 ± 1.2%, feces 39.9 ± 5.9%) with 0.08 ± 0.03% remaining in the body. The concentration of radioactivity in all organs and tissues was below 0.1 ppm.
All Group B animals excreted> 90% of the administered radioactivity after two days. The mean total recovery from males was 105.9 ± 3.1% (urine 44.5 ± 3.2%, feces 61.1 ± 5.6%) with a mean residual level of radioactivity in the body of 0.05 ± 0.01%. The corresponding recovery in females was 104.0 ± 1.7% (urine 50.5 ± 2.7%, feces 53.1 ± 1.5%) with 0.07 ± 0.01% remaining in the body. The concentration of radioactivity in all organs and tissues was below 0.1 ppm.
All Group C animals excreted > 90% of the administered radioactivity after three days. All surviving female rats excreted > 80% of the administered radioactivity after three days. The mean total recovery from males was 98.8 ± 5.7% (urine 49.3 ± 5.5%, feces 48.9 ± 4.5%) with a mean total of 0.12 ± 0.07% remaining in the body. The corresponding recovery in females was 95.5 ± 2.2% (urine 52.5 ± 5.0%, feces 42.3 ± 7.1%) with 0.12 ± 0.01% remaining in the body. The concentration of radioactivity in the organs and tissues ranged from "not detectable" to about 8.8 ppm in the kidneys in rat CM2.
All Group D animals excreted > 80% of the administered radioactivity after three days. The mean total recovery from males was 101.0 ± 4.3% (urine 51.3 ± 9.2%, feces 48.9 ± 6.7%) with a mean total of 0.04 ± 0.02% remaining in the body. The corresponding recovery in females was 93.8 ± 8.6% (urine 39.6 ± 16.3%, feces 53.5 ± 7.8%) with 0.13 ± 0.13% remaining in the body. The concentration of radioactivity in the organs and tissues ranged from "not detectable" to about 11 ppm in the fat in rat DF5.
The test substance is moderately metabolized (~ 50%) when administered orally to rats at a low- dose level (10 mg/kg), both with and without preconditioning, and at a high-dose level (1000 mg/kg). An overall similarity of male and female metabolism of the test substance was demonstrated. Two major metabolites were identified by LC/MS as the N-Demethyl and the O-Deethyl metabolite. A minor metabolite, which was found consistently in all samples analyzed, was identified as the Free Acid. A dose-dependent metabolism was observed. At the low-dose level, the N-Demethyl metabolite was the major metabolite in urine; whereas at the high-dose level, the O-Deethyl metabolite was the predominant metabolite in the urine.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.